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http://dx.doi.org/10.1016/j.jmii.2012An 89-year-old man suffered from and died of necrotizing pneumonia with rapid progression
and cavity formation due to methicillin-resistant Staphylococcus aureus (MRSA). He was at
no risk for hospital-acquired MRSA infection. His MRSA exhibited genotype ST5/spa2(t002)/
agr2/SCCmecII/coagulaseII and was negative for PantoneValentine leukocidin, indicating the
New York/Japan clone (the predominant epidemic hospital-acquired MRSA clone in Japan).
However, this strain expressed the cytolytic peptide (phenol-soluble modulin or d-hemolysin)
genes at high level, similar to USA300 (the most common community-acquired MRSA in the
United States), indicating a variant of the New York/Japan clone with an important feature
of community-acquired MRSA.
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Methicillin-resistant Staphylococcus aureus (MRSA) has
been a common nosocomial pathogen since 19611; this class
of MRSA is now called hospital-acquired MRSA (HA-MRSA).
HA-MRSA generally possesses staphylococcal cassette
chromosomemec (SCCmec) type I, II, or III and is multidrug-
resistant.1,2 The traditional healthcare-associated risk for
acquisition of MRSA includes surgery, residence in a long-
term care facility, dialysis, indwelling percutaneous
medical devices and catheters, and age (50e60 years and
older).3e6
Previous studies7e12 and our unpublished data (in
2006e2011) suggested that multilocus sequence type (ST)
5/SCCmecII MRSA (the epidemic New York/Japan clone) is
currently the predominant clone in hospitals in Japan; this
clone in Japan is also characterized by the carriage of
SaPIm1/n1 (with the tst, sec, and sel genes) and entero-
toxin gene cluster (egc; with the seg, sei, sem, sen, and seo
genes) and multiple-drug resistance (including levofloxacin
or fosfomycin resistance). The New York/Japan clone
(Japanese type with SaPIm1/n1) has also been isolated
from Taiwan.13
Another class of MRSA, designated community-acquired
MRSA (CA-MRSA), emerged in the community from 1997 to
1999.1,5,14 CA-MRSA generally carries SCCmec type IV or V,
is resistant to b-lactam agents only or to some agents
belonging to limited classes, and often produces
PantoneValentine leukocidin (PVL),1,5,14 which causesFigure 1. (A) Chest X-ray on days 6e13 and the (B) transaxial
community-acquired necrotizing pneumonia. In (A), arrows indicat
middle lung field; they showed fast radiological progression (days 6
In (B), multiple cavity lesions within the consolidation are seen inapoptosis and necrosis in human polymorphonuclear cells or
monocytes.15 CA-MRSA infections are associated mainly
with skin and soft tissue infections (SSTIs), but occasionally
with invasive infections such as bacteremia (and sepsis) and
necrotizing pneumonia in healthy individuals, especially
children and adolescents (such as athletes) or even the
elderly1,3e5,14; median ages of CA-MRSA and HA-MRSA
patients are 23 and 68 years, respectively.3
ST8/SCCmecIVa MRSA USA300, the most common CA-
MRSA clone in the United States, is one of the most well-
characterized CA-MRSA2,16; USA300 is positive for PVL and
the arginine catabolic mobile element (ACME), and
produced a greater amount of cytolytic peptide [phenol-
soluble modulins (PSMs) or d-hemolysin (Hld)] than HA-
MRSA.16
In Japan, the New York/Japan clone (HA-MRSA) has also
been spreading in the community, among healthy children
and pediatric outpatients,17 and even on public transport18;
however, the association of this New York/Japan clone
(nasal or public transport MRSA) with diseases in the
community has not been reported. In this report, we
describe the first necrotizing pneumonia case caused by the
New York/Japan MRSA clone in the community in Japan. In
this study, CA-MRSA and HA-MRSA were classified according
to a previous definition4; CA-MRSA is defined as MRSA iso-
lated from outpatients with no history of hospitalization
within at least the past year and who presented with no
other established risk factors for HA-MRSA infections
(except age).and coronal sections of chest CT on day 10 of a patient with
e pulmonary infiltrates with multiple cavity lesions in the right
e13). Bilateral pulmonary infiltrates in the lungs are also seen.
the right upper and middle lobes.
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An 89-year-old man was admitted to a hospital on March 14,
2007 (day 1), because of progressive dyspnea. White blood
cell count and C-reactive protein were 9300/mL and
11.5 mg/dL, respectively. Chest computed tomography
revealed centrilobular nodules mainly in the right lung,
with a small volume of right pleural effusion. He had
hemoptysis on day 4 and disseminated intravascular coag-
ulation on day 6. On the same day, chest radiography
revealed multiple cavities in the right lung (Fig. 1A). Since
MRSA was detected upon sputum culture (including day 1),
necrotizing pneumonia by MRSA was suspected (blood
culture examination was negative for MRSA). Although he
was treated with teicoplanin (800 or 400 mg/day), clinda-
mycin (1.2 g/day), and pazufloxacin (1 g/day), increased
multiple cavities and bilateral pleural effusion were
observed on day 10 (Fig. 1B), and multiple organ failure
developed. He died on day 15. He had had no risk factors
for HA-MRSA in the past year and no previous MRSA infec-
tions. His MRSA, epidemiologically classified as CA-MRSA,
was named NPk1.
Next, we investigated the molecular characteristics of
MRSA strain NPk1. Molecular typing and virulence geneTable 1 Molecular characteristics of the patient’s MRSA strain
clone (in Japan)
Type, virulence gene, drug resistance
NPk1
Type
ST 5
spa 2 (t002)
agr 2
SCCmec type II.1.1.1
Coagulase type II
Virulence gene
Leukocidin
lukEelukD þ
Hemolysin
hla þ
hlg, hlg-v þ
hlb (þ)b
Peptide cytolysin
psma, hld þ
Enterotoxin
SaPIm1/n1 (tst, sec, sel ) þ
egc (seg, sei, sem, sen, seo) þ
Adhesin
c12agc þ
Drug resistance (non-b lactams)d ERY, CLI, KAN, LV
a Reference strains (Mu50 and N315) of the New York/Japan clone (
b hlb (þ), split hlb gene due to insertion of bacteriophage.
c c12ag, core 12 adhesin genes shared by all strains: icaA, icaD (fo
fibronectineadhesin); ebpS (for elastineadhesin); clfA, clfB, fib, sdrC
d CLI Z clindamycin; ERY Z erythromycin; FOF Z fosfomycin;
TET Z tetracycline; VAN Z vancomycin.analysis were performed as described previously.13,19
Susceptibility testing of MRSA was carried out using the
agar dilution method according to previous procedures
described by the Clinical and Laboratory Standards Insti-
tute.20 Breakpoints for drug resistance were those
described by the Clinical and Laboratory Standards Insti-
tute.20 MRSA strain NPk1 shared the same genotype (ST5/
spa2[t002]/agr2/SCCmecII.1.1.1[II]/CoaII) and the same
virulence genes (including SaPIm1/n1 and egc) as the
epidemic New York/Japan clone of HA-MRSA (reference
strains Mu50 and N315), as shown in Table 1. Strain NPk1
was multidrug-resistant, but to fewer classes of agents than
the reference strains (e.g., strain NPk1 was susceptible to
fosfomycin).
Since staphylococcal superantigens, such as toxic shock
syndrome toxin-1 (TSST-1) and staphylococcal enterotoxin
B, are associated with pulmonary disease in an animal
model21 and ST8 CA-MRSA/J (a major CA-MRSA in Japan,
which was associated with invasive infections including
necrotizing pneumonia) produced TSST-1 at a high level,19
TSST-1 production levels (the amount of TSST-1 in the
supernatant of bacterial cultures at 2.0  l09 cfu/ml) were
examined using a TST-RPLA kit (Denka Seiken, Tokyo,
Japan). The TSST-1 production level of strain NPk1 wasNPk1 compared to reference strains of the New York/Japan
MRSA strain
New York/Japana
Mu50 N315
5 5
2 (t002) 2 (t002)
2 2
II.1.1.1 II.1.1.1
II II
þ þ
þ þ
þ þ
(þ)b (þ)b
þ þ
þ þ
þ þ
þ þ
X ERY, CLI, GEN, KAN,
TET, FOF, LVX, VAN
ERY, CLI, GEN, KAN,
TET, FOF, LVX
in Japan) were kindly provided by K. Hiramatsu.
r biofilm formation); eno (for laminineadhesin); fnbA, fnbB (for
, sdrD, sdrE (for fibrinogeneadhesin).
GEN Z gentamicin; KAN Z kanamycin; LVX Z levofloxacin;
338 O. Khokhlova et al.200 mg/ml, and was relatively similar to those of the New
York/Japan clone, including reference strains [Mu50
(800 mg/ml) and N315 (50 mg/ml)] and clinical isolates from
TSS patients [I6 (200 mg/ml) and I8 (200 mg/ml)], although
the TSST-1 production level of strain NPk1 was lower than
that of ST8 CA-MRSA/J (6400 mg/ml).19
Finally, the mRNA expression levels of the cytolytic
peptide genes [psma (encoding PSMa) and hld (encoding
Hld)], hla (encoding a-hemolysin, Hla; alternatively named
a-toxin), and 16S rRNA genes were examined by reverse
transcription-polymerase chain reaction (RT-PCR) assay, as
described previously.19 Briefly, total RNA was extracted and
purified from the bacterial cells, cultured at 37 C for 8 h,
using the RNAprotect Bacteria Reagent and RNeasy Mini Kit
(Qiagen, Valencia, CA, USA) according to the manufac-
turer’s instructions. RT of the RNA sample was achieved
using the SuperScript First-Strand Synthesis System for
RT-PCR (Invitrogen, Carlsbad, CA) according to the manu-
facturer’s instructions. The cDNA products of the psma,
hld, hla, and 16S rRNA genes were amplified by PCR using
the reported PCR primers.13,22,23 PCR products were elec-
trophoresed on 2% agarose gel and then stained with
ethidium bromide. After visualization of PCR products by
ultraviolet illumination, band intensity was determined
using image processing and analyzing software (NIH Image;
NIH, Bethesda, MD, USA), and psma, hld, or hla expression
was normalized by 16S rRNA expression. For statistical
analysis, data were evaluated by Student’s t-test. The level
of significance was defined as p < 0.05. As shown in Fig. 2,
for either the psma or hld gene, mRNA expression levels of
community isolates of the New York/Japan clone (includingFigure 2. The levels of mRNA expression for cytolytic
peptide genes (psma and hld ) and hla of MRSA strain NPk1,
compared to those of the New York/Japan clone (Japanese
type) and USA300. Community isolates of the New York/Japan
clone included strain NPk1 (Table 1) and two isolates from
a child and public transport. Inpatient isolates of the New
York/Japan clone (nZ 8) included reference strains Mu50 and
N315 (Table 1), two MRSA isolates from patients with toxic
shock syndrome, and four isolates from sputum and blood,
which were randomly selected. USA300 included USA300-0114,
a type strain of USA300 (it was kindly provided by L.K.
McDougal and L.L. McDonald), and three clinical isolates in
Japan. psma, hld, or hla expression was normalized by 16S
rRNA expression. Data (mean  SD) were obtained from three
experiments.strain NPk1) were similar to those of ST8 CA-MRSA USA300,
but significantly higher than those of inpatient isolates of
the New York/Japan clone (p < 0.05). In contrast, the
mRNA expression levels of the hla gene were similar among
the three groups (community and inpatient isolates of the
New York/Japan clone and USA300) (Fig. 2).Discussion
This study represents the first case of fatal community-
acquired pneumonia (CAP), with rapid progression and
cavity formation (with pleural effusion), caused by the New
York/Japan clone (strain NPk1). Although pleural infiltrates
with multiple nodular and cavity lesions have been noted
especially for necrotizing pneumonia caused by PVL-
positive CA-MRSA,24 this study was a PVL-negative case.
Moreover, cavity formation may be observed in some cases
of CAP from methicillin-susceptible S. aureus and Klebsiella
pneumoniae and in septic pulmonary embolism, but it is not
usually observed in HA-MRSA infections in Japan; therefore,
this case indicates the involvement of a strong virulence
factor(s) (other than PVL) in the pathogenesis of fatal
necrotizing pneumonia.
In the case of USA300, remarkable virulence markers
involve PVL (possibly related to pneumonia, albeit with
controversial data in animal models),15 ACME (possibly
related to colonization),16 Hla (possibly related to necro-
tizing pneumonia),16 and enhanced production levels of
cytolytic peptides PSMs and Hld (possibly related to invasive
infections)16; the hla, psm, and hld genes are generally
present in all S. aureus strains. PSMa (20e22 amino acids)
and Hld (26 amino acids) cause cell lysis of human poly-
morphonuclear neutrophils and are also a potent inducer of
chemotaxis and interleukin-8 production of poly-
morphonuclear neutrophils.25
Strain NPk1 was negative for the PVL gene and ACME;
however, it expressed the cytolytic peptide (PSMa and Hld)
genes at higher levels than HA-MRSA (New York/Japan
clone); the expression levels were similar to USA300 and
a successful CA-MRSA clone (ST8 CA-MRSA/J) in Japan,
which we recently characterized as a cause of CAP,19 indi-
cating that strain NPk1 is a variant of the New York/Japan
clone with an important feature of CA-MRSA.
Strain NPk1 also produced Hla and TSST-1; the expres-
sion levels of the hla gene were similar among HA- and CA-
MRSA strains examined, and the TSST-1 production level of
strain NPk1 was similar to those of HA-MRSA inpatient
strains. We speculate that the combination (in synergy) of
a high amount of cytolytic peptides (PSMa and Hld), Hla,
superantigens (such as TSST-1), and others contributed to
the pathogenesis of severe MRSA CAP in Japan (although the
patient was elderly in this case).
In Japan, the New York/Japan clone has mainly been
isolated in hospitals, but it has also been isolated from
children (mainly 5- to 9-year-old) in the community (albeit
at low frequencies: 0.4% [1/274]); no nasal MRSA has been
isolated from university students (<0.2%; 0/526).17 Chil-
dren are frequently treated as outpatients at hospitals near
their homes, so it is conceivable that some children carry
the New York/Japan clone from hospitals, and transmission
of such MRSA occurs among their family members, because
Elderly MRSA pneumonia in the community 339MRSA colonizing the nares could also be detected on their
hands.2,23 This may be the case even for elderly people.
Most probably reflecting these situations, the New York/
Japan clone is also detected from the straps and handrails
of trains (public transport) in Japan18; of 15 MRSA isolates,
two were the New York/Japan clone (13.3%).
These community isolates of the New York/Japan clone
expressed the cytolytic peptide (PSMa and Hld) genes at
high levels (similar to NPk1), in contrast to inpatient
isolates of the New York/Japan clone. There is a possibility
that the New York/Japan clone with enhanced expression
of the cytolytic peptide genes has been selected in the
community and caused fatal CAP in an elderly individual.
This case may pose a threat, since the elderly population
has been increasing. Further detailed analysis with more
strains is needed.References
1. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E.
Emergence and resurgence of methicillin-resistant Staphylo-
coccus aureus as a public-health threat. Lancet 2006;368:
874e85.
2. Diep BA, Stone GG, Basuino L, Graber CJ, Miller A, des
Etages SA, et al. The arginine catabolic mobile element and
staphylococcal chromosomal cassette mec linkage: conver-
gence of virulence and resistance in the USA300 clone of
methicillin-resistant Staphylococcus aureus. J Infect Dis 2008;
197:1523e30.
3. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ,
Etienne J, et al. Comparison of community- and health care-
associated methicillin-resistant Staphylococcus aureus infec-
tion. JAMA 2003;290:2976e84.
4. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S,
et al. Invasive methicillin-resistant Staphylococcus aureus
infections in the United States. JAMA 2007;298:1763e71.
5. Yamamoto T, Nishiyama A, Takano T, Yabe S, Higuchi W,
Razvina O, et al. Community-acquired methicillin-resistant
Staphylococcus aureus: community transmission, pathogen-
esis, and drug resistance. J Infect Chemother 2010;16:
225e54.
6. Harinstein L, Schafer J, D’Amico F. Risk factors associated with
the conversion of methicillin-resistant Staphylococcus aureus
colonisation to healthcare-associated infection. J Hosp Infect
2011;79:194e7.
7. Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, Kobayashi I,
et al. Whole genome sequencing of methicillin-resistant
Staphylococcus aureus. Lancet 2001;357:1225e40.
8. Oliveira DC, Tomasz A, de Lencastre H. Secrets of success of
a human pathogen: molecular evolution of pandemic clones of
methicillin-resistant Staphylococcus aureus. Lancet Infect Dis
2002;2:180e9.
9. Chongtrakool P, Ito T, Ma XX, Kondo Y, Trakulsomboon S,
Tiensasitorn C, et al. Staphylococcal cassette chromosomemec
(SCCmec) typing of methicillin-resistant Staphylococcus aureus
strains isolated in 11 Asian countries: a proposal for a new
nomenclature for SCCmec elements. Antimicrob Agents Che-
mother 2006;50:1001e12.
10. Zaraket H, Otsuka T, Saito K, Dohmae S, Takano T, Higuchi W,
et al. Molecular characterization of methicillin-resistant
Staphylococcus aureus in hospitals in Niigata, Japan: diver-
gence and transmission. Microbiol Immunol 2007;51:171e6.11. Ohkura T, Yamada K, Okamoto A, Baba H, Ike Y, Arakawa Y,
et al. Nationwide epidemiological study revealed the dissem-
ination of methicillin-resistant Staphylococcus aureus carrying
a specific set of virulence-associated genes in Japanese
hospitals. J Med Microbiol 2009;58:1329e36.
12. Yanagihara K, Araki N, Watanabe S, Kinebuchi T, Kaku M,
Maesaki S, et al. Antimicrobial susceptibility and molecular
characteristics of 857 methicillin-resistant Staphylococcus
aureus isolates from 16 medical centers in Japan (2008e2009):
nationwide survey of community-acquired and nosocomial
MRSA. Diagn Microbiol Infect Dis 2012;72:253e7.
13. Takano T, Higuchi W, Otsuka T, Baranovich T, Enany S, Saito K,
et al. Novel characteristics of community-acquired methicillin-
resistant Staphylococcus aureus strains belonging to multilocus
sequence type 59 in Taiwan. Antimicrob Agents Chemother
2008;52:837e45.
14. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-
acquired methicillin-resistant Staphylococcus aureus: an
emerging threat. Lancet Infect Dis 2005;5:275e86.
15. Lo¨ffler B, Hussain M, Grundmeier M, Bru¨ck M, Holzinger D,
Varga G, et al. Staphylococcus aureus PantoneValentine leu-
kocidin is a very potent cytotoxic factor for human neutrophils.
PLoS Pathog 2010;6:e1000715.
16. Diep BA, Otto M. The role of virulence determinants in
community-associated MRSA pathogenesis. Trends Microbiol
2008;16:361e9.
17. Ozaki K, Takano M, Higuchi W, Takano T, Yabe S, Nitahara Y,
et al. Genotypes, intrafamilial transmission, and virulence
potential of nasal methicillin-resistant Staphylococcus aureus
from children in the community. J Infect Chemother 2009;15:
84e91.
18. Iwao Y, Yabe S, Takano T, Higuchi W, Nishiyama A,
Yamamoto T. Isolation and molecular characterization of
methicillin-resistant Staphylococcus aureus (MRSA) from public
transport. Microbiol Immunol 2012;56:76e82.
19. Iwao Y, Ishii R, Tomita Y, Shibuya Y, Takano T, Hung WC, et al.
The emerging ST8 methicillin-resistant Staphylococcus aureus
clone in the community in Japan: associated infections genetic
diversity, and comparative genomics. J Infect Chemother
2012;18:228e40.
20. Clinical and Laboratory Standards Institute. Performance
standard for antimicrobial susceptibility testing; 21st infor-
mational supplement. Approved standard M100eMS21.
Wayne, PA: CLSI; 2011.
21. Strandberg KL, Rotschafer JH, Vetter SM, Buonpane RA,
Kranz DM, Schlievert PM. Staphylococcal superantigens cause
lethal pulmonary disease in rabbits. J Infect Dis 2010;202:
1690e7.
22. Li M, Cheung GY, Hu J, Wang D, Joo HS, Deleo FR, et al.
Comparative analysis of virulence and toxin expression of
global community-associated methicillin-resistant Staphylo-
coccus aureus strains. J Infect Dis 2010;202:1866e76.
23. Yamamoto T, Takano T, Yabe S, Higuchi W, Iwao Y, Isobe H,
et al. Super-sticky familial infections caused by Pan-
toneValentine leukocidin-positive ST22 community-acquired
methicillin-resistant Staphylococcus aureus in Japan. J Infect
Chemother 2012;18:187e98.
24. Defres S, Marwick C, Nathwani D. MRSA as a cause of lung
infection including airway infection, community-acquired
pneumonia and hospital-acquired pneumonia. Eur Respir J
2009;34:1470e6.
25. Wang R, Braughton KR, Kretschmer D, Bach TH, Queck SY, Li M,
et al. Identification of novel cytolytic peptides as key virulence
determinants for community-associated MRSA. Nat Med 2007;
13:1510e4.
